A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia

Aplastic Anemia Clinical Trial

— OSP  

Official title:

A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02203396
• Other study ID #: ATGIIT201401
• Status: Recruiting
• Phase: Phase 2
• First received: July 27, 2014
• Last updated: May 3, 2016
• Start date: August 2014
• Est. completion date: September 2017

Study information

• Verified date: May 2016
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Nie Neng
• Email: docnn[@]163.com
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Severe acquired aplastic anaemia (SAA) is a bone marrow failure disease characterized by pancytopenia and a hypocellular bone marrow. The corn pathophysiological mechanism is the destruction of hematopoietic stem/progenitor cells mediated by auto-reactive effector T cells. Immunosuppressive therapy with horse antithymocyte globulin (ATG) plus cyclosporine (CSA) is currently the standard of treatment in patients with aplastic anaemia who are not eligible for bone marrow transplantation and with response rates from 40% to 70%. Previous studies showed that horse ATG (hATG) is apparently more effective than rabbit ATG (rATG) as the latter has higher treatment related mortality (TRM). Unfortunately hATG is unavailable in China, so we conduct a optimized standard treatment (9 days protocol) of rATG plus CSA and Levamisole (LMS) Sequential maintaining (termed Optimized Standard Protocol, OSP) for severe aplastic anemia. This prospective study is designed to evaluate the efficacy and safety of Optimized Standard Protocol as first line therapy in newly diagnosed severe aplastic anemia patients.

Description:

During the treatment period, rATG is administered at a dose of 1.97 mg/kg/day for 9 days by slow intravenous infusion. CSA is administered orally at a dose of 3 mg/kg qod, and Levamisole was administered orally at a dose of 2.5 mg/kg qod. The CSA and Levamisole (LMS) is designed to alternately every other day.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 2017
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Years to 70 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed SAA (according to the standard criteria)

1. Bone marrow cellularity less than 30% (excluding lymphocytes)

2. At least two of the following: Absolute neutrophil count less than 500/ uL; Platelet count less than 20,000/ uL; Absolute reticulocyte count less than 20,000/ uL.

• Age greater than or equal to 6 years old

Exclusion Criteria:

• Serum creatinine greater than 2.5 mg/dL

• Underlying carcinoma (except local cervical, basal cell, squamous cell)

• Prior immunosuppressive therapy with ATG, antilymphocyte globulin (ALG), or high dose cyclophosphamide.

• Current pregnancy or lactation or unwillingness to take oral contraceptives or use an effective method of birth control.

• Diagnosis of Fanconi anemia or other congenital bone marrow failure syndromes

• Evidence of a clonal disorder on cytogenetics. Patients with super severe neutropenia (ANC less than 200/uL) will not be excluded if results of cytogenetics are not available or pending.

• Underlying immunodeficiency state including seropositivity for HIV

• Inability to understand the investigational nature of the study or give informed consent

• Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 7-10 days is likely.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia
• Anemia, Aplastic
• Aplastic Anemia

Intervention

Drug:
• rabbit ATG, Cyclosporine, Levamisole
rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.

Locations

Country	Name	City	State
China	Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences	TianJin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Yizhou Zheng

Country where clinical trial is conducted

China, 

References & Publications (2)

Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975 Mar;45(3):355-63. — View Citation

Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003 Mar 5;289(9):1130-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the response and complete remission rate with Optimized Standard Protocol.	Response will be evaluated at each clinic visit. Complete response (CR) was defined as achieving all three peripheral blood count criteria: (1) Hb level up to the normal range; (2) ANC=1.5×109/L; (3) PLT=100×109/L.; Partial response (PR) was defined as transfusion independent, no longer meeting criteria for severe disease. Persistence of transfusion requirement or death was evidence of no response (NR).	month +6	No
Secondary	Relapse rate, sustained response (SR), survival, and clonal evolution to myelodysplasia and acute leukemia.	Relapse was defined as a responder who met criteria for SAA again after achieving response and keeping stable blood counts for at least 3 months.; Sustained response (SR) was defined as Hb > 10 g/dL at month +12 and +60, in the absence of any treatment.	month +12, month +60	No